shortness

Most of our competitors emphasize the importance of "deep 'prior art' searches." In their efforts to show you how technically capable they are, they seem to forget the importance of returning results that (1) are interpretable, (2) have practical meaning, and (3) are transparently sophisticated. Our promise to you is that we will continue to focus on the types of questions you need answered and will improve our patent search tools based on your needs. At IPstreet.com, we use a very sophisticated search technology called "Concept Searching" that allows you to enter a lengthy description of your invention, product, or idea, and compare it to the universe of granted patents and patent applications in the United States using data from the USPTO. Using our patent analytic search tools, we offer you patent analytics software that is sophisticated, transparent, and meaningful results. Our patent search tools are top of the line. We understand patent searches are important when answering the questions, is my idea patentable, how to patent an idea and what is the best patent search service available?

During development, IP Street was very fortunate and grateful to have early partners that signed on to use our tools, often in beta form. Through timely and constructive feedback, our partners were instrumental in helping us develop features that evolved from "interesting and cool" to "nice to have" to "got to have". Below is a sampling of some of the enterprise partners who understood our vision very early on. They became annual subscribers and were afforded the benefits of having direct access to our development team, enabling us to design more relevant tools and allowing them to enjoy influence in design priorities. They include: Alibaba, Amazon, Lee & Hayes, PAML, T-Mobile. Thank you to all of our enterprise partners.

Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.